Furthermore, in the GSE109211 and GSE104580 treatment cohorts for HCC, we observed that patients with high SF3B6 expression exhibited more pronounced resistance to sorafenib and TACE treatment. The gene discussed is SF3B6; the disease is hepatocellular carcinoma.